R848@M2pep-MPsAFP and anti-PD-1 antibody combination treatment exhibited the strongest anticancer activity, resulting in 50% of mice being almost cured and 83.3% of mice being still alive at 80 days after tumor inoculation. Here, PDCD1 is linked to neoplasm.